Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
about
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Immunotherapy in acute myeloid leukemia.Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
P2860
Q34360641-1F7D43BE-2767-418F-ABA1-E3986DC42BE3Q34380060-2AE6E8B1-37B3-4D05-BE18-9EEEE3E5BCD3Q35641272-E44232BA-E946-4458-9EF2-E33CC86476D0Q35800814-17441538-91C6-4908-9C49-A3FD50B88325Q36264692-8E2F20AF-D1FC-48F3-AA28-5F1B85966F8BQ38191280-5D953B28-8ECB-4E88-9941-1AEC96C96D3FQ38199056-3B73DC01-08C3-4346-9701-282A96D902E5Q38533606-546156D1-4958-4721-9C3F-6DAAAC43B593Q39488956-10FD1CFD-432E-4741-ACCC-8D683C948B60Q40396484-760D74FF-4595-4653-9B0E-29B2D9F18FA4Q40438036-667E368D-EB7F-4889-B20B-FA3496F90D68Q41519709-6ADABB15-832D-4FB8-B5E4-2D15EBE9AB72Q44462895-83FE2DB1-2241-4FC8-AC6E-7851B7A6013FQ45233774-7EE8D9E0-69C3-4719-BFC5-0E06456CB11BQ47724804-8BF2F837-E754-4584-9FD9-20CAF1792480Q49790702-4832A33D-3229-4F5C-BEA0-7A5D6A7E2BA6Q53162006-B99C1938-71B9-44E0-A287-12578C835BDFQ54509279-2602ABDE-EC2A-435E-8E88-B50C18EBEB92Q55380860-81D96B0E-ED3F-4F0B-B40F-6847045164D9
P2860
Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimizing the conditioning re ...... se intensity is still in need.
@en
Optimizing the conditioning re ...... se intensity is still in need.
@nl
type
label
Optimizing the conditioning re ...... se intensity is still in need.
@en
Optimizing the conditioning re ...... se intensity is still in need.
@nl
prefLabel
Optimizing the conditioning re ...... se intensity is still in need.
@en
Optimizing the conditioning re ...... se intensity is still in need.
@nl
P1476
Optimizing the conditioning re ...... se intensity is still in need.
@en
P2093
Arnon Nagler
Avichai Shimoni
P304
P356
10.1016/J.BEHA.2011.05.002
P577
2011-06-24T00:00:00Z